Loading the section…

INM: financial statements from SEC — TradeAlmanac

INM

InMed Pharmaceuticals Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	30/06/2025	30/06/2024
Revenue	5M	5M
Cost of revenue	3M	3M
Gross profit	2M	1M
Research and development	3M	3M
Selling, general and administrative	7M	6M
Operating expenses	10M	9M
Pre-tax income	−8M	−8M
Income tax	—	7,100
Net income	−8M	−8M
Earnings per share	−8.36	−20.14
Earnings per share, diluted	−8.36	−20.14
Weighted average shares	975,985	381,053
Weighted average shares, diluted	975,985	381,053

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	5M	7M	9M	11M	5M	3M	6M	7M
Short-term investments	41,625	42,675	42,859

Cash flow

Metric	30/06/2025	30/06/2024
Operating cash flow	−8M	−7M
Depreciation and amortisation	212,839	219,600
Share-based compensation	119,307	137,714
Capital expenditure	—	9,293
Investing cash flow	—	−9,293
Financing cash flow

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator